Skip to main content
Premium Trial:

Request an Annual Quote

William Gerber, Heiner Dreismann, Van Wyck Brinkerhoff, Deborah Smeltzer, Avril Hamilton

Premium
William Gerber, a non-independent member of the Nanogen's board of directors, resigned from the board effective May 1, the company said this week.
 
Nanogen said Gerber’s resignation restores compliance with Nasdaq Marketplace Rule 4350(c)(1), which requires a majority of members of the board of directors to be comprised of independent directors.
 
The non-compliance resulted from the appointment of Heiner Dreismann, a non-independent director, to the company's board on Oct. 31, 2006, Nanogen said.
 

 
Gene Logic has promoted Van Wyck Brinkerhoff to the post of senior vice president of administration. He will receive a $100,000 cash incentive bonus and a $250,000 executive cash incentive target for 2007.
 
Brinkerhoff joined Gene Logic in 2005 as senior vice president and general manager for its preclinical contract research business.
 
Prior to joining Gene Logic, he was group vice president for operations at Wilson Greatbatch Technologies. Earlier, he held senior management positions with Life Technologies, now Invitrogen.
 

 
ExonHit Therapeutics has appointed Deborah Smeltzer to its supervisory board. Smeltzer is CFO and vice president of operations at Dynavax Technologies. She formerly was vice president and general manager of Applied Biosystems’genetic-analysis business, and had been CFO and a vice president at Genset.
 

 
MWG Biotech has tapped Avril Hamilton for the post of UK and Ireland sales manager, and hired Krish Sakhamuru as key account salesperson.
 
Before joining MWG, Hamilton was senior European territory manager at Cogenics and was in sales at PerkinElmer and Bio-Rad.
 
Sakhamuru was an account manager with Elsevier MDL and Informax.
 

The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.